Waqar Haque1, K Ranh Voong2, Ferial Shihadeh2, Isidora Arzu2, Chelsea Pinnix2, Ali Mazloom2, L Jeffrey Medeiros3, Jorge Romaguera4, Alma Rodriguez4, Michael Wang4, Pamela Allen2, Bouthaina Dabaja5. 1. Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX. 2. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. 3. Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX. 5. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: bdabaja@mdanderson.org.
Abstract
INTRODUCTION: Mantle cell lymphoma has an aggressive clinical course and continuous relapse pattern with a median survival of 3 to 7 years. Multiple courses of chemotherapy are the basis of treatment. Radiotherapy is underutilized in this disease. We undertook this study to assess the role of radiation therapy. MATERIALS AND METHODS: A total of 41 consecutive patients with mantle cell lymphoma diagnosed from December, 1999 to January, 2010 who received radiation therapy were reviewed retrospectively. The main endpoint was in-field lymphoma response at each irradiated disease site. RESULTS: There were 39 evaluable patients (68 symptomatic sites). Sites treated included: nodal stations (n = 31), soft tissue (n = 13), mucosal sites (n = 11), central nervous system (n = 10), gastrointestinal tract (n = 2), and bone (n = 1). Median maximum tumor size at presentation was 3.5 cm (range, 1.3 cm-9.6 cm). The median dose of radiation was 30.6 Gy (range 18-40 Gy). Median follow-up post radiation per site was 12.3 months (range, 0.6-80.9 months). Response to treatment was complete in 47 sites (69.1%), partial in 16 sites (23.5%), and 5 sites (7.4%) had stable disease. In 9 (13.2%) sites local relapse occurred (median 7 months; range 2-21). The mean size of lymphoma at time of RT correlated with relapse, with tumors with local relapse larger than those without a local relapse (P = .005). CONCLUSIONS: Our data add to accumulating evidence that mantle cell lymphoma is a radio-sensitive disease with excellent responses to relatively low radiation doses, even in patients with chemo-refractory disease.
INTRODUCTION:Mantle cell lymphoma has an aggressive clinical course and continuous relapse pattern with a median survival of 3 to 7 years. Multiple courses of chemotherapy are the basis of treatment. Radiotherapy is underutilized in this disease. We undertook this study to assess the role of radiation therapy. MATERIALS AND METHODS: A total of 41 consecutive patients with mantle cell lymphoma diagnosed from December, 1999 to January, 2010 who received radiation therapy were reviewed retrospectively. The main endpoint was in-field lymphoma response at each irradiated disease site. RESULTS: There were 39 evaluable patients (68 symptomatic sites). Sites treated included: nodal stations (n = 31), soft tissue (n = 13), mucosal sites (n = 11), central nervous system (n = 10), gastrointestinal tract (n = 2), and bone (n = 1). Median maximum tumor size at presentation was 3.5 cm (range, 1.3 cm-9.6 cm). The median dose of radiation was 30.6 Gy (range 18-40 Gy). Median follow-up post radiation per site was 12.3 months (range, 0.6-80.9 months). Response to treatment was complete in 47 sites (69.1%), partial in 16 sites (23.5%), and 5 sites (7.4%) had stable disease. In 9 (13.2%) sites local relapse occurred (median 7 months; range 2-21). The mean size of lymphoma at time of RT correlated with relapse, with tumors with local relapse larger than those without a local relapse (P = .005). CONCLUSIONS: Our data add to accumulating evidence that mantle cell lymphoma is a radio-sensitive disease with excellent responses to relatively low radiation doses, even in patients with chemo-refractory disease.
Authors: Matthew S Ning; Chelsea C Pinnix; Bhavana V Chapman; Jillian R Gunther; Sarah A Milgrom; Joseph D Khoury; Preetesh Jain; Wendy Y Chen; Onyeka N Oriabure; Maria R Badillo; L Michael Wang; Bouthaina S Dabaja Journal: Blood Adv Date: 2019-07-09
Authors: Chelsea C Pinnix; Bouthaina S Dabaja; Sarah A Milgrom; Grace L Smith; Zeinab Abou; Loretta Nastoupil; Jorge Romaguera; Francesco Turturro; Nathan Fowler; Luis Fayad; Jason Westin; Sattva Neelapu; Michelle A Fanale; Maria A Rodriguez; Frederick Hagemeister; Hun Ju Lee; Yasuhiro Oki; Michael Wang; Felipe Samaniego; Linda Chi; Bita Esmaeli Journal: Head Neck Date: 2017-04-03 Impact factor: 3.147
Authors: Manuel Weber; Walter Jentzen; Regina Hofferber; Ken Herrmann; Wolfgang Peter Fendler; Christoph Rischpler; Lale Umutlu; Maurizio Conti; Pedro Fragoso Costa; Miriam Sraieb; David Kersting Journal: BMC Cancer Date: 2021-01-14 Impact factor: 4.430
Authors: Pedro Fragoso Costa; Walter Jentzen; Alissa Brahmer; Ilektra-Antonia Mavroeidi; Fadi Zarrad; Lale Umutlu; Wolfgang P Fendler; Christoph Rischpler; Ken Herrmann; Maurizio Conti; Robert Seifert; Miriam Sraieb; Manuel Weber; David Kersting Journal: BMC Cancer Date: 2022-08-18 Impact factor: 4.638
Authors: Arati A Inamdar; Andre Goy; Nehad M Ayoub; Christen Attia; Lucia Oton; Varun Taruvai; Mark Costales; Yu-Ting Lin; Andrew Pecora; K Stephen Suh Journal: Oncotarget Date: 2016-07-26